Due to a delay in raw material components, Baxter will be experiencing a product shortage on both formats of Sandoz Vitamin K1 Injections (2 mg/mL and 10 mg/mL). These products are manufactured by Sandoz Canada and distributed by Baxter Corporation. Vitamin K is recommended for all newborns and is to be given within the first 6 hours of life. Baxter has limited the release of Vitamin K (inj) products until the issue is resolved; this is anticipated to be mid-October 2018. In the meantime, Baxter and Sandoz are asking that hospitals work to conserve product where possible and to work collaboratively to share limited resources during this shortage.
Read the full memo from Baxter.